ClinicalTrials.gg
RecruitingNCT06966635Updated May 13, 2025

Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets

A Phase 4 interventional study of Sodium Bicarbonate Oral Capsule and Potassium Citrate Tablets in Hyperuricemia or Gout and Nephrolithiasis, sponsored by Huashan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Huashan Hospital · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Apr 2024, registered May 2025).
  • Started Apr 2024; still recruiting 2 years 7 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To evaluate whether alkalization has the effect of lowering uric acid and reducing gout flare and determine whether alkalization has a role in the prevention and treatment of urinary calculi in gout, the research participants were divided into the control group, the potassium citrate group and the sodium bicarbonate group. 2 alkalization groups took potassium citrate three times a day 2.16g each time, or sodium bicarbonate three times a day, 1.0g each time, on the basis of the standard uric acid-lowering treatment plan. The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable.

02

Conditions studied

  • Hyperuricemia or Gout
  • Nephrolithiasis
03

In context

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

This study's planned enrollment of 312 is above the median of 68 across 193 interventional studies indexed under Hyperuricemia.

Browse Hyperuricemia studies →

Lead sponsor

Huashan Hospital is the lead sponsor of 247 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) for gout in 2015
  • Age 18-70 years old, gender is not limited
  • The interval between the most recent acute onset of gout is at least > 2 weeks
  • Routine treatment with stable dose of uric-lowering drugs for > 4 weeks
  • For women who are likely to become pregnant, pregnancy tests must be negative, they must not be lactating, they must be using an investigator-approved method of , and they must agree to maintain this method of contraception throughout the study
  • Study participants were informed, voluntarily signed , and agreed to participate in all visits, examinations, and treatments as required by the trial protocol
  • Informed consent to the purpose and content of the research.

Exclusion criteria

Exclusion Criteria:

  • Acute gout flare
  • Secondary gout caused by kidney disease, blood disease, or taking certain drugs, tumor radiotherapy and chemotherapy
  • Severe and unstable cardiovascular and cerebrovascular diseases (such as unstable angina pectoris, coronary angiogenesis, cerebral angiogenesis, , congestive heart failure, etc.), acute and difficult to control diseases, chronic diffuse connective tissue disease, xanthine urethral deposition, Lesch-Nyhan syndrome, untreated thyroid disease or kidney stones, treatment Patients with severe hypertension (blood pressure > 160/100mmHg) or diabetes (fasting blood glucose > 11.1mmol/L) and organ transplantation that were not effectively controlled later
  • People who are allergic, have a history of allergy to test-related drugs (febuxosita tablets, allopurinol tablets, benzbromarone, etoracoxib, colchicine, potassium citrate, etc.) or are allergic to test-related drug components
  • Active peptic ulcer or ulcer with bleeding and perforation, severe chronic diarrhea or recurrent skin disease in the past year
  • Blood white blood cell count \< 3.0x109/L, \< 90g/L, count \< 100x109/L, or other blood system diseases (such as severe anemia, idiopathic thrombocytopenic purpura, spleen enlargement, coagulation dysfunction, etc.)
  • Active stage of liver disease or abnormal liver function ( or AST≥2 times the )
  • Patients with abnormal renal function (≤60ml/min/1.73m\^2)
  • Patients with elevated blood potassium (5.5mmol/L) may have diseases or factors that may lead to hyperkalemia, such as type IV renal tubular acidosis and widespread tissue injury
  • Urine PH value > 6.5 during screening
  • Combined use of the following drugs: Contains salicylate drugs such as aspirin (> 300mg/d), thiazide diuretics, potassium diuretics such as amphenopterine, Amiloride, ACEI, azathioprine, 6-mercaptopurine, theophylline, losartan, cyclosporin A, cyclophospfamide, pyrazinamide, (except in acute episodes), Niergoline tablets, long-term use of insulin, Digitalis
  • Women who are pregnant, planning to become pregnant or breastfeeding mental illness, no self-knowledge, unable to accurately express or can not take drugs on time
  • A history of alcohol abuse or dependence on known drugs within the last two years
  • Those who have participated or are participating in other clinical trials within three months
  • The study participant is a family member or relative of the staff of the research Center
  • Other lesions or conditions that, in the investigator's judgment, reduce or complicate enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (estimated)

Study arms

  • Active comparator
    Controll group

    The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone.

    Drug: uric-acid-lowering drug

  • Experimental
    Potassium citrate group

    On the basis of the standard uric acid-lowering treatment plan, potassium citrate was taken three times a day, 2.16g each time.

    Drug: Potassium Citrate Tablets · Drug: uric-acid-lowering drug

  • Experimental
    Sodium bicarbonate group

    Sodium Bicarbonate Oral Capsule

    Drug: Sodium Bicarbonate Oral Capsule · Drug: uric-acid-lowering drug

Interventions

  • On the basis of the standard uric acid-lowering treatment plan, sodium bicarbonate should be taken three times a day, 1.0g each time

  • On the basis of the standard uric acid-lowering treatment plan, potassium citrate was taken three times a day, 2.16g each time

  • Druguric-acid-lowering drug

    The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable. The treatment plan for lowering uric acid remained unchanged for 4 weeks after enrollment in the clinical study until the endpoint.

06

What researchers measure

Primary outcomes

  1. serum uric acid

    Time frame: From enrollment to the end of treatment at 48 weeks

Secondary outcomes

  1. gout flare

    Time frame: From enrollment to the end of treatment at 48 weeks

Other outcomes

  1. nephrolithiasis

    Time frame: From enrollment to the end of treatment at 48 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all IPD collected throughout the trial. Contact the author by email after the research is completed.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 3 months and ending 3 years after the publication of results

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06966635
Lead sponsor
Huashan Hospital
Responsible party
Zhu Xiaoxia (Associate Chief Physician, Huashan Hospital) — Principal investigator
First posted
May 13, 2025
Start date
Apr 10, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
May 13, 2025

Study contacts

Yu Miao
Contact
my20000109@126.com
021-17857540080

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sodium Bicarbonate · Potassium Citrate

Start the discussion